What You Should Know:
- Phenomix Sciences, a precision medicine biotechnology company, released findings from a new survey revealing a growing demand for personalized obesity care.
- The survey of 475 patients explored attitudes toward weight management, treatment preferences, and information sources.
Key Findings:
Patients Seek Medical Guidance: A majority of respondents (66%) prefer guidance from healthcare providers to manage weight loss, highlighting the need for a
Read More
GLP-1
Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable
What You Should Know:
- A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.
- The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community's views on the rapidly growing class of GLP-1 medications, often hailed as
Read More
Nestlé Health Science Launches Innovative GLP-1 Nutrition Platform
What You Should Know:
- Nestlé Health Science, a global leader in nutritional science, today announced the launch of glp-1nutrition.com, a web platform designed to support individuals on their weight management journey, particularly those using GLP-1 medications.
- The launch of glp-1nutrition.com reflects their ongoing commitment to empowering healthier lives through targeted nutritional guidance.
GLP-1nutrition.com: Your One-Stop Shop for GLP-1 Weight Management Support
The
Read More
Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use
What You Should Know:
- Aranscia, a leader in personalized diagnostics, and Signature RX, a prominent pharmacy supplier, announced a collaborative effort to improve the effectiveness of GLP-1 medications.
- The multi-phase partnership focuses on developing personalized treatment plans and ensuring consistent access to these crucial medications.
GLP-1s: Beyond Type 2 Diabetes
Glucagon-like peptide-1 receptor agonists (GLP-1s) were initially developed for type 2 diabetes
Read More
Weekly Ozempic/Wegovy Injections May Lower Kidney Failure Risk, Study Finds
What You Should Know:
- A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 diabetes and chronic kidney disease (CKD).Find semaglutide online today.
- Funded by Novo Nordisk creators of Ozempic and Wegovy semaglutide injections for diabetes management, the study published in The New England Journal of Medicine investigated
Read More
Dandelion Health Launches First Multimodal GLP-1 Data Library for Precision Medicine
What You Should Know:
- Dandelion Health, a leader in real-world data (RWD) and clinical AI, has unveiled the industry's first-ever multimodal GLP-1 data library.
- The multimodal GLP-1 data library empowers researchers and life sciences companies to unlock deeper insights into the use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for precision medicine.
Unprecedented Depth of Real-World Data
Gathered from Dandelion's network of collaborating medical centers,
Read More
LifeMD Integrates with Withings: GLP-1 Weight Loss with In-Home Monitoring
What You Should Know:
- LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD's GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2 scale and
Read More
Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery
What You Should Know:
- Lexaria Bioscience Corp. is pushing the boundaries of oral drug delivery with their latest clinical trial.
- The company announced they have contracted a research organization (CRO) to conduct a second human pilot study on their DehydraTECH-powered glucagon-like peptide-1 (GLP-1) treatment.
GLP-1 Challenges and Lexaria's Solution
GLP-1 drugs, like semaglutide, are currently delivered through injections or tablets. However, these methods have limitations.
Read More
Teladoc Health Expands Obesity & Weight Management Capabilities with GLP-1 Support
What You Should Know:
Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as glucagon-like peptide 1 (GLP-1) agonists and support safe, sustainable weight loss and cardiometabolic health improvement for members.New features include helping plan sponsors and pharmacy benefit managers manage and optimize the growing complexity and
Read More
WeightWatchers Launches First-Of-Its-Kind GLP-1 Program + WeightWatchers Clinic
What You Should Know:
- WeightWatchers launches two new offerings to further support individuals on their journeys to better health: the WeightWatchers GLP-1 Program and WeightWatchers Clinic integration within the WeightWatchers App.
- By focusing on personalization, scientific evidence, and comprehensive support, WW empowers individuals to take control of their weight health and achieve lasting results.
WeightWatchers GLP-1 Program
This program addresses the unique needs of
Read More
